|
Name |
Heminigerone
|
Molecular Formula | C16H14O5 | |
IUPAC Name* |
5-hydroxy-6,8-dimethoxy-2-methylbenzo[g]chromen-4-one
|
|
SMILES |
CC1=CC(=O)C2=C(C3=C(C=C(C=C3C=C2O1)OC)OC)O
|
|
InChI |
InChI=1S/C16H14O5/c1-8-4-11(17)15-13(21-8)6-9-5-10(19-2)7-12(20-3)14(9)16(15)18/h4-7,18H,1-3H3
|
|
InChIKey |
HFPQKJMLIONCGP-UHFFFAOYSA-N
|
|
Synonyms |
Heminigerone; Rubrofusarin B; TMD 256a2; TMD-256a2; 17276-15-2; CHEMBL469613; TLJ90R747F; 5-hydroxy-6,8-dimethoxy-2-methylbenzo[g]chromen-4-one; 4H-Naphtho(2,3-b)pyran-4-one, 5-hydroxy-6,8-dimethoxy-2-methyl-; UNII-TLJ90R747F; rubrofusarin monomethyl ether; SCHEMBL16227248; DTXSID50169393; CHEBI:133805; BDBM50241852; Q27290019; 5-hydroxy-6,8-dimethoxy-2-methyl-benzo[g]chromen-4-one; 5-HYDROXY-6,8-DIMETHOXY-2-METHYL-4H-BENZO[G]CHROMEN-4-ONE; 5-hydroxy-6,8-dimethoxy-2-methyl-4H-naphtho(2,3-b)pyran-4-one
|
|
CAS | 17276-15-2 | |
PubChem CID | 176918 | |
ChEMBL ID | CHEMBL469613 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 286.28 | ALogp: | 3.3 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 21 | QED Weighted: | 0.726 |
Caco-2 Permeability: | -4.814 | MDCK Permeability: | 0.00001750 |
Pgp-inhibitor: | 0.052 | Pgp-substrate: | 0.127 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.641 |
Blood-Brain-Barrier Penetration (BBB): | 0.06 | Plasma Protein Binding (PPB): | 80.84% |
Volume Distribution (VD): | 0.836 | Fu: | 14.41% |
CYP1A2-inhibitor: | 0.972 | CYP1A2-substrate: | 0.974 |
CYP2C19-inhibitor: | 0.645 | CYP2C19-substrate: | 0.713 |
CYP2C9-inhibitor: | 0.664 | CYP2C9-substrate: | 0.915 |
CYP2D6-inhibitor: | 0.603 | CYP2D6-substrate: | 0.915 |
CYP3A4-inhibitor: | 0.4 | CYP3A4-substrate: | 0.249 |
Clearance (CL): | 5.178 | Half-life (T1/2): | 0.507 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.137 |
Drug-inuced Liver Injury (DILI): | 0.791 | AMES Toxicity: | 0.486 |
Rat Oral Acute Toxicity: | 0.12 | Maximum Recommended Daily Dose: | 0.625 |
Skin Sensitization: | 0.778 | Carcinogencity: | 0.051 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.877 |
Respiratory Toxicity: | 0.561 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002363 | 0.776 | D06GCK | 0.460 | ||||
ENC001770 | 0.758 | D0G4KG | 0.405 | ||||
ENC003752 | 0.624 | D04AIT | 0.318 | ||||
ENC006013 | 0.589 | D0FA2O | 0.313 | ||||
ENC001495 | 0.578 | D0D4HN | 0.288 | ||||
ENC001417 | 0.574 | D0W7JZ | 0.284 | ||||
ENC000938 | 0.532 | D0K8KX | 0.283 | ||||
ENC004732 | 0.529 | D07MGA | 0.280 | ||||
ENC002207 | 0.529 | D02LZB | 0.279 | ||||
ENC004845 | 0.526 | D0B0AX | 0.278 |